Molecular architecture responsible for specific inhibition of oncogenic PI3Kα mutants by RLY-2608 and STX-478
Abstract
Hotspot mutations in phosphoinositide 3-kinase alpha (PI3K α ), such as H1047R, E542K, and E545K, drive tumorigenesis across multiple cancer types. Orthosteric PI3K α inhibitors are effective but have toxicity against wild-type PI3K α , the emergence of resistance, and a narrow therapeutic index. Allosteric inhibitors such as RLY-2608 and STX-478 offer a promising path toward mutant-specific suppression, yet the structural basis for their selectivity and mechanisms of action remain elusive. Here, we report high-resolution cryogenic electron microscopy structures of RLY-2608- and STX-478-bound H1047R, E542K, and E545K, revealing a shared cryptic allosteric pocket, accessible only through a major conformational rearrangement of the activation loop that is stabilized in oncogenic mutants. While both inhibitors occupy this pocket, they have distinct interaction networks and propagate divergent allosteric activities: RLY-2608 induces large-scale remodeling of catalytic and membrane-interacting elements, whereas STX-478 reinforces autoinhibitory interfaces between p110 α and p85 α subunits. Comparative analysis provides structural insights into their differentiated potency and selectivity.
Fields of Study & Subjects
PI3K/AKT/mTOR signaling in cancer
RNA Research and Splicing
Biochemical and Molecular Research
Publication details
- Journal / source
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Volume
- 16
- Issue
- 9
- Pages
- 5884–5900
- Publication date
- 5 July 2026
- Language
- EN